Graham P. Marsh
Graham P. Marsh has a total of 178 co-authors. Here are the top co-authors by number of shared publications:
- Hannah Jane Maple
Bio-Techne (Tocris), The Watkins Building, Atlantic Road, Avonmouth, Bristol BS11 9QD, U.K.
13 shared publications Mark S. Cooper
Bio-Techne (Tocris), The Watkins Building, Atlantic Road, Avonmouth, Bristol, BS11 9QD, UK
5 shared publications- John Spencer
Department of Chemistry School of Life Sciences University of Sussex Brighton UK
4 shared publications Mark C. Norley
Bio-Techne (Tocris), The Watkins Building, Avonmouth, Bristol, UK
4 shared publicationsAnthony K. Edmonds
Chemistry Department, School of Life Sciences
3 shared publications- Anthony K. Edmonds
Bio-Techne (Tocris), The Watkins Building, Avonmouth, Bristol, UK
3 shared publications
Latest Publications
- Open Access
- 13 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
BromoCatch: a self-labelling tag platform for protein modification and live cell imaging
Visualizing and manipulating proteins in live cells is crucial for studying complex biological processes. Self-labelling protein (SLP) tags such as HaloTag and SNAP-tag are widely used for protein labelling, and new systems are needed to expand multiplexing capabilities and broaden the scope of applications. Here we present BromoCatch, a small ~13 kDa bromodomain (BD)-based SLP platform, engineered with a nucleophilic cysteine for covalent ligand engagement. A structure-based designed library of electrophilic ligands was screened against two cysteine-containing mutants using differential scanning fluorimetry and intact protein mass spectrometry to assess covalent complex formation. We identified a para-acrylamide bumped derivative MR116 and the Brd4-BD2 double mutant L387A,E438C as the optimal protein-ligand pair, and reveal the binding mode through an X-ray co-crystal structure solved to 1.3 Å resolution. BromoCatch demonstrated potent and irreversible cellular target engagement in NanoBRET and residence-time assays. Its versatility was demonstrated through the design of a biotinylated conjugate, PROTAC-based degraders, and fluorescent full-on and “switch-on” probes for ex-cellulo and live-cell imaging, including side-by-side comparison and orthogonality with HaloTag. Together, these results establish BromoCatch as a robust, modular, and orthogonal SLP tool with broad potential for multiplexed labelling and targeted protein manipulation.
- 13 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessBromoCatch: a self-labelling tag platform for protein modification and live cell imaging
Visualizing and manipulating proteins in live cells is crucial for studying complex biological processes. Self-labelling protein (SLP) tags such as HaloTag and SNAP-tag are widely used for protein labelling, and new systems are needed to expand multiplexing capabilities and broaden the scope of applications. Here we present BromoCatch, a small ~13 kDa bromodomain (BD)-based SLP platform, engineered with a nucleophilic cysteine for covalent ligand engagement. A structure-based designed library of electrophilic ligands was screened against two cysteine-containing mutants using differential scanning fluorimetry and intact protein mass spectrometry to assess covalent complex formation. We identified a para-acrylamide bumped derivative MR116 and the Brd4-BD2 double mutant L387A,E438C as the optimal protein-ligand pair, and reveal the binding mode through an X-ray co-crystal structure solved to 1.3 Å resolution. BromoCatch demonstrated potent and irreversible cellular target engagement in NanoBRET and residence-time assays. Its versatility was demonstrated through the design of a biotinylated conjugate, PROTAC-based degraders, and fluorescent full-on and “switch-on” probes for ex-cellulo and live-cell imaging, including side-by-side comparison and orthogonality with HaloTag. Together, these results establish BromoCatch as a robust, modular, and orthogonal SLP tool with broad potential for multiplexed labelling and targeted protein manipulation.
- Open Access
- 6 October 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-16
Discovery of a CNS active GSK3 degrader using orthogonally reactive linker screening
Bifunctional targeted protein degraders, also known as Proteolysis Targeting Chimeras (PROTACs), are an emerging drug modality that may offer a new approach for treating neurodegenerative diseases. Identifying chemical starting points for PROTACs remains a largely empirical process and the design rules for identifying Central Nervous System (CNS) active PROTACs have yet to be established. Here we demonstrate a concept of using orthogonally reactive linker reagents, that allow the construction of screening libraries whereby the E3 ligase binder, the target protein binder and the linker can be simultaneously varied and tested directly in cellular assays. This approach enabled the discovery of Glycogen Synthase Kinase 3 (GSK3) PROTACs which are CNS in vivo active in female mice. Our findings provide opportunities to investigate the role of GSK3 paralogs in cellular and in vivo disease models and for the rapid discovery of in vivo quality bifunctional chemical probes for CNS disease concepts.
- 6 October 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-16
Open AccessDiscovery of a CNS active GSK3 degrader using orthogonally reactive linker screening
Bifunctional targeted protein degraders, also known as Proteolysis Targeting Chimeras (PROTACs), are an emerging drug modality that may offer a new approach for treating neurodegenerative diseases. Identifying chemical starting points for PROTACs remains a largely empirical process and the design rules for identifying Central Nervous System (CNS) active PROTACs have yet to be established. Here we demonstrate a concept of using orthogonally reactive linker reagents, that allow the construction of screening libraries whereby the E3 ligase binder, the target protein binder and the linker can be simultaneously varied and tested directly in cellular assays. This approach enabled the discovery of Glycogen Synthase Kinase 3 (GSK3) PROTACs which are CNS in vivo active in female mice. Our findings provide opportunities to investigate the role of GSK3 paralogs in cellular and in vivo disease models and for the rapid discovery of in vivo quality bifunctional chemical probes for CNS disease concepts.
- Open Access
- 17 April 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (9) , 9638-9660
Structure-Guided Design of ISOX-DUAL-Based Degraders Targeting BRD4 and CBP/EP300: A Case of Degrader Collapse
Degraders with dual activity against BRD4 and CBP/EP300 were designed. A structure-guided design approach was taken to assess and test potential exit vectors on the dual BRD4 and CBP/EP300 inhibitor, ISOX-DUAL. Candidate degrader panels revealed that VHL-recruiting moieties could mediate dose-responsive ubiquitination of BRD4. A panel of CRBN-recruiting thalidomide-based degraders was unable to induce ubiquitination or degradation of target proteins. High-resolution protein cocrystal structures revealed an unexpected interaction between the thalidomide moiety and Trp81 on the first bromodomain of BRD4. The inability to form a ternary complex provides a potential rationale for the lack of degrader activity with these compounds, some of which have remarkable affinities close to those of (+)-JQ1, as low as 65 nM in a biochemical assay, vs 1.5 μM for their POI ligand, ISOX-DUAL. Such a "degrader collapse" may represent an under-reported mechanism by which some putative degrader molecules are inactive with respect to target protein degradation.
- 17 April 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (9) , 9638-9660
Open AccessStructure-Guided Design of ISOX-DUAL-Based Degraders Targeting BRD4 and CBP/EP300: A Case of Degrader Collapse
Degraders with dual activity against BRD4 and CBP/EP300 were designed. A structure-guided design approach was taken to assess and test potential exit vectors on the dual BRD4 and CBP/EP300 inhibitor, ISOX-DUAL. Candidate degrader panels revealed that VHL-recruiting moieties could mediate dose-responsive ubiquitination of BRD4. A panel of CRBN-recruiting thalidomide-based degraders was unable to induce ubiquitination or degradation of target proteins. High-resolution protein cocrystal structures revealed an unexpected interaction between the thalidomide moiety and Trp81 on the first bromodomain of BRD4. The inability to form a ternary complex provides a potential rationale for the lack of degrader activity with these compounds, some of which have remarkable affinities close to those of (+)-JQ1, as low as 65 nM in a biochemical assay, vs 1.5 μM for their POI ligand, ISOX-DUAL. Such a "degrader collapse" may represent an under-reported mechanism by which some putative degrader molecules are inactive with respect to target protein degradation.
- Open Access
BromoCatch: a self-labelling tag platform for protein analysis and live cell imaging
Visualizing and manipulating proteins in live cells is crucial for studying complex biological processes. Self-labelling protein (SLP) tags such as HaloTag and SNAP-tag can be fused to genes of interest to allow protein labelling in cells. Limitations including size of the tag and suboptimal fitness of reactivity motivate development of improved tools to enable rapid, specific and stable protein labelling. We present BromoCatch, a novel SLP platform based on a small ∼13 kDa bromodomain (BD) engineered with a nucleophilic cysteine for covalent ligand engagement. A structure-based designed library of 16 “bumped” binders bearing diverse electrophilic warheads was screened against two different cysteine mutants using differential scanning fluorimetry and intact protein mass spectrometry to monitor covalent complex formation. The para-acrylamide bumped derivative MR116 and the Brd4-BD2 double mutant L387A,E438C formed the most potent and stable adduct, and its binding mode through covalent modification was confirmed by an X-ray cocrystal structure solved to 1.3 Å of resolution. BromoCatch exhibited potent and irreversible target engagement in cells through nanoBRET and residence time assays. Practicality and scope are further demonstrated through the design and proof-of-concept application of a biotinylated conjugate, PROTAC tag degraders, and fluorescent probes of both full-on and switch-on types for ex-cellulo and live-cell imaging. Together, we qualify BromoCatch as a novel, versatile and efficient protein labelling tool and technology platform. Its advantageous design features and kinetic fitness, and its modular design enabling diverse functionalities, are anticipated to usher a range of future applications and witness broad utility.
Open AccessBromoCatch: a self-labelling tag platform for protein analysis and live cell imaging
Visualizing and manipulating proteins in live cells is crucial for studying complex biological processes. Self-labelling protein (SLP) tags such as HaloTag and SNAP-tag can be fused to genes of interest to allow protein labelling in cells. Limitations including size of the tag and suboptimal fitness of reactivity motivate development of improved tools to enable rapid, specific and stable protein labelling. We present BromoCatch, a novel SLP platform based on a small ∼13 kDa bromodomain (BD) engineered with a nucleophilic cysteine for covalent ligand engagement. A structure-based designed library of 16 “bumped” binders bearing diverse electrophilic warheads was screened against two different cysteine mutants using differential scanning fluorimetry and intact protein mass spectrometry to monitor covalent complex formation. The para-acrylamide bumped derivative MR116 and the Brd4-BD2 double mutant L387A,E438C formed the most potent and stable adduct, and its binding mode through covalent modification was confirmed by an X-ray cocrystal structure solved to 1.3 Å of resolution. BromoCatch exhibited potent and irreversible target engagement in cells through nanoBRET and residence time assays. Practicality and scope are further demonstrated through the design and proof-of-concept application of a biotinylated conjugate, PROTAC tag degraders, and fluorescent probes of both full-on and switch-on types for ex-cellulo and live-cell imaging. Together, we qualify BromoCatch as a novel, versatile and efficient protein labelling tool and technology platform. Its advantageous design features and kinetic fitness, and its modular design enabling diverse functionalities, are anticipated to usher a range of future applications and witness broad utility.
- Open Access
- 10 March 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Discovery of a CNS active GSK3 degrader using orthogonally reactive linker screening
Bifunctional targeted protein degraders, also known as Proteolysis Targeting Chimeras (PROTACs), are an emerging drug modality that may offer a new approach to understand and treat neurodegenerative diseases. These molecules have a non-occupancy based, sub-stoichiometric mechanism of action which results in removal of target proteins from cells, presenting new opportunities to interrogate and intervene in pathogenic signalling. Identifying chemical starting points for PROTACs remains a largely empirical process and the design rules for identifying in vivo quality tools to interrogate new therapeutic hypotheses in the Central Nervous System (CNS) have yet to be established. We demonstrate a concept of using orthogonally reactive linker reagents, that allowed us to construct screening libraries varying the E3 ligase recruiting ligand, the target protein recruiting ligand and the linker simultaneously and test compounds directly in cells. This led us identify a molecule directly from our screen that upon further profiling demonstrated rapid and selective Glycogen Synthase Kinase 3 (GSK3) degradation in cells, as well as CNS in vivo activity in mouse. Our findings provide new opportunities to investigate the role of GSK3 paralogs in cellular and in vivo disease models and demonstrate a successful Direct-to-Biology approach, with broad potential for identifying in vivo quality bifunctional chemical probes for CNS disease concepts.
- 10 March 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessDiscovery of a CNS active GSK3 degrader using orthogonally reactive linker screening
Bifunctional targeted protein degraders, also known as Proteolysis Targeting Chimeras (PROTACs), are an emerging drug modality that may offer a new approach to understand and treat neurodegenerative diseases. These molecules have a non-occupancy based, sub-stoichiometric mechanism of action which results in removal of target proteins from cells, presenting new opportunities to interrogate and intervene in pathogenic signalling. Identifying chemical starting points for PROTACs remains a largely empirical process and the design rules for identifying in vivo quality tools to interrogate new therapeutic hypotheses in the Central Nervous System (CNS) have yet to be established. We demonstrate a concept of using orthogonally reactive linker reagents, that allowed us to construct screening libraries varying the E3 ligase recruiting ligand, the target protein recruiting ligand and the linker simultaneously and test compounds directly in cells. This led us identify a molecule directly from our screen that upon further profiling demonstrated rapid and selective Glycogen Synthase Kinase 3 (GSK3) degradation in cells, as well as CNS in vivo activity in mouse. Our findings provide new opportunities to investigate the role of GSK3 paralogs in cellular and in vivo disease models and demonstrate a successful Direct-to-Biology approach, with broad potential for identifying in vivo quality bifunctional chemical probes for CNS disease concepts.
- Open Access
- 3 March 2025
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 16 (5) , 2049-2060
Development of p300-targeting degraders with enhanced selectivity and onset of degradation
P300 and CBP are paralogous epigenetic regulators and promising therapeutic targets for which TPD offers the potential to achieve paralog-selective degradation.
- 3 March 2025
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 16 (5) , 2049-2060
Open AccessDevelopment of p300-targeting degraders with enhanced selectivity and onset of degradation
P300 and CBP are paralogous epigenetic regulators and promising therapeutic targets for which TPD offers the potential to achieve paralog-selective degradation.
- Open Access
- 18 February 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Structure-guided design of ISOX-DUAL-based Degraders targeting BRD4 and CBP/EP300. A case of Degrader collapse
Degraders with dual activity against BRD4 and CBP/EP300 were designed. A structure-guided design approach was taken to assess and test potential exit vectors on the dual BRD4 and CBP/EP300 inhibitor, ISOX-DUAL. Candidate Degrader panels revealed that VHL-recruiting moieties could mediate dose-responsive ubiquitination of BRD4. A panel of CRBN-recruiting thalidomide-based Degraders were unable to induce ubiquitination or degradation of target proteins. High-resolution protein co-crystal structures revealed an unexpected interaction between the thalidomide moiety and Trp81 on the first bromodomain of BRD4. The inability to form a ternary complex provides a potential rationale for the lack of Degrader activity with these compounds, some of which have remarkable affinities close to those of (+)-JQ1, as low as 65 nM in a biochemical assay, vs 1.5 M for their POI ligand, ISOX-DUAL. Such a “Degrader collapse” may represent an under-reported mechanism by which some putative Degrader molecules are inactive with respect to target protein degradation.
- 18 February 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessStructure-guided design of ISOX-DUAL-based Degraders targeting BRD4 and CBP/EP300. A case of Degrader collapse
Degraders with dual activity against BRD4 and CBP/EP300 were designed. A structure-guided design approach was taken to assess and test potential exit vectors on the dual BRD4 and CBP/EP300 inhibitor, ISOX-DUAL. Candidate Degrader panels revealed that VHL-recruiting moieties could mediate dose-responsive ubiquitination of BRD4. A panel of CRBN-recruiting thalidomide-based Degraders were unable to induce ubiquitination or degradation of target proteins. High-resolution protein co-crystal structures revealed an unexpected interaction between the thalidomide moiety and Trp81 on the first bromodomain of BRD4. The inability to form a ternary complex provides a potential rationale for the lack of Degrader activity with these compounds, some of which have remarkable affinities close to those of (+)-JQ1, as low as 65 nM in a biochemical assay, vs 1.5 M for their POI ligand, ISOX-DUAL. Such a “Degrader collapse” may represent an under-reported mechanism by which some putative Degrader molecules are inactive with respect to target protein degradation.
- Open Access
- 16 January 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (3) , 2920-2941
Structure-Based Optimization of Pyridone α-Ketoamides as Inhibitors of the SARS-CoV-2 Main Protease
The main protease Mpro is a clinically validated target to treat infections by the coronavirus SARS-CoV-2. Among the first reported Mpro inhibitors was the peptidomimetic α-ketoamide 13b, whose cocrystal structure with Mpro paved the way for multiple lead-finding studies. We established structure-activity relationships for the 13b series by modifying residues at the P1', P3, and P4 sites. Guided by cocrystal structures, we reduced the P1' substituent size to better fill the pocket and added a fluorine substituent to the pyridone ring, enabling a new hydrogen bond with Gln189 in P3. Among 22 novel analogues, 6d and 12d inhibited Mpro with IC50s of 110 nM and 40 nM, improving the potency of 13b by up to 9.5-fold. Compound 6d had pronounced antiviral activity with an EC50 of 1.6 μM and was stable in plasma and microsomes. The study illustrates the potential of structure-based design to systematically improve peptidomimetic α-ketoamides.
- 16 January 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (3) , 2920-2941
Open AccessStructure-Based Optimization of Pyridone α-Ketoamides as Inhibitors of the SARS-CoV-2 Main Protease
The main protease Mpro is a clinically validated target to treat infections by the coronavirus SARS-CoV-2. Among the first reported Mpro inhibitors was the peptidomimetic α-ketoamide 13b, whose cocrystal structure with Mpro paved the way for multiple lead-finding studies. We established structure-activity relationships for the 13b series by modifying residues at the P1', P3, and P4 sites. Guided by cocrystal structures, we reduced the P1' substituent size to better fill the pocket and added a fluorine substituent to the pyridone ring, enabling a new hydrogen bond with Gln189 in P3. Among 22 novel analogues, 6d and 12d inhibited Mpro with IC50s of 110 nM and 40 nM, improving the potency of 13b by up to 9.5-fold. Compound 6d had pronounced antiviral activity with an EC50 of 1.6 μM and was stable in plasma and microsomes. The study illustrates the potential of structure-based design to systematically improve peptidomimetic α-ketoamides.
- 15 January 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (3) , 3591-3611
Evaluation of Cereblon-Directing Warheads for the Development of Orally Bioavailable PROTACs
PROTACs usually occupy physicochemical space outside the one defined by classical drug-like molecules, which often presents considerable challenges in their optimization and development for oral administration. We have previously reported phenyl glutarimide (PG)-based BET PROTAC SJ995973, with improved overall in vitro degradation and antiproliferative activities compared to its direct thalidomide-based analogue dBET1, but similarly poor in vivo pharmacokinetic profile. To further demonstrate the PG utility, we describe here optimization efforts that led to the discovery of an orally bioavailable BET-PROTAC SJ44236 (8), and results of a comprehensive in vitro/vivo comparative study with analogues containing alternative CRBN-directing warheads. Our study highlights the importance of considering warhead modifications when optimizing PROTACs for oral delivery.
- 15 January 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (3) , 3591-3611
Evaluation of Cereblon-Directing Warheads for the Development of Orally Bioavailable PROTACs
PROTACs usually occupy physicochemical space outside the one defined by classical drug-like molecules, which often presents considerable challenges in their optimization and development for oral administration. We have previously reported phenyl glutarimide (PG)-based BET PROTAC SJ995973, with improved overall in vitro degradation and antiproliferative activities compared to its direct thalidomide-based analogue dBET1, but similarly poor in vivo pharmacokinetic profile. To further demonstrate the PG utility, we describe here optimization efforts that led to the discovery of an orally bioavailable BET-PROTAC SJ44236 (8), and results of a comprehensive in vitro/vivo comparative study with analogues containing alternative CRBN-directing warheads. Our study highlights the importance of considering warhead modifications when optimizing PROTACs for oral delivery.
- 4 October 2023
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 21 (41) , 8344-8352
Efficient, multi-hundred-gram scale access to E3 ubiquitin ligase ligands for degrader development
Supporting degrader discovery programs in scale and scope: facile access to multi-hundred-gram quantities of the common E3 ligase ligands.
- 4 October 2023
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 21 (41) , 8344-8352
Efficient, multi-hundred-gram scale access to E3 ubiquitin ligase ligands for degrader development
Supporting degrader discovery programs in scale and scope: facile access to multi-hundred-gram quantities of the common E3 ligase ligands.